Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Autor: Ganz PA; University of California, Los Angeles, Los Angeles, CA.; Jonsson Comprehensive Cancer Center, Los Angeles, CA., Bandos H; NRG Oncology SDMC, The University of Pittsburgh, Pittsburgh, PA., Španić T; Europa Donna-The European Breast Cancer Coalition, Milan, Italy.; Europa Donna Slovenia, Ljubljana, Slovenia., Friedman S; Facing Our Risk of Cancer Empowered, Tampa, FL., Müller V; Depatment of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Kuemmel S; Breast Unit, Kliniken Essen-Mitte, Essen, Germany.; Department of Gynecology with Breast Center, Charité-Universitätsmedizin Berlin, Berlin, Germany., Delaloge S; Gustave Roussy, Villejuif, France., Brain E; Department of Medical Oncology, Institut Curie, Saint-Cloud, France., Toi M; Kyoto University Hospital, Kyoto, Japan.; Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan., Yamauchi H; St Luke's International Hospital, Tokyo, Japan., de Dueñas EM; Consorcio Hospitalario Provincial de Castellón, Castellón, Spain.; GEICAM Spanish Breast Cancer Group, Madrid, Spain., Armstrong A; Department of Medical Oncology, Division of Cancer Sciences, The University of Manchester, The Christie Hospital, Manchester, United Kingdom., Im SA; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Song CG; Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, China., Zheng H; West China Hospital, Sichuan University, Chengdu, China., Sarosiek T; Luxmed Onkologia, Warsaw, Poland., Sharma P; University of Kansas Medical Center, Westwood, KS., Geng C; The Fourth Hospital of Hebei Medical University, Shiijazhuang, China., Fu P; Breast Surgery Department, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China., Rhiem K; Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Cologne, Germany., Frauchiger-Heuer H; Breast Center Unit, UniversitätsSpital Zürich, Zürich, Switzerland., Wimberger P; Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Dresden, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., t'Kint de Roodenbeke D; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Liao N; Guangdong People's Hospital, Guangzhou, China., Goodwin A; Concord Repatriation General Hospital, University of Sydney, Sydney, NSW, Australia., Chakiba-Brugère C; Département d'oncologie médicale, Institut Bergonié, Bordeaux, France., Friedlander M; Prince of Wales Clinical School, University of NSW and Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, NSW, Australia., Lee KS; Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea., Giacchetti S; Breast Disease Unit (Sénopole), AP-HP, Hôpital Saint-Louis, Paris, France., Takano T; Breast Medical Oncology Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan., Henao-Carrasco F; Hospital Universitario Virgen Macarena GEICAM Spanish Breast Cancer Group, Sevilla, Spain., Virani S; Advocate Aurora Health, Milwaukee, WI., Valdes-Albini F; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Domchek SM; Basser Center for BRCA, University of Pennsylvania, Philadelphia, PA., Bane C; Dayton Physicians Network, Dayton, OH., McCarron EC; MedStar Franklin Square Medical Center-Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD., Mita M; Cedars Sinai Medical Center, SOCCI, Los Angeles, CA., Rossi G; Breast International Group (BIG), Brussels, Belgium., Rastogi P; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.; Magee Women's Hospital, Pittsburgh, PA., Fielding A; Oncology R&D, AstraZeneca, Gaithersburg, MD., Gelber RD; Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Boston, MA.; Frontier Science Foundation, Boston, MA., Scheepers ED; Frontier Science (Scotland), Kincraig, United Kingdom., Cameron D; University of Edinburgh, Edinburgh, United Kingdom., Garber J; Dana-Farber/Harvard Cancer Center, Boston, MA., Geyer CE; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA., Tutt ANJ; The Institute of Cancer Research London, London, United Kingdom.; Kings College London, London, United Kingdom.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 10; Vol. 42 (11), pp. 1288-1300. Date of Electronic Publication: 2024 Feb 01.

Preclinical and clinical development of palbociclib and future perspectives.

Autor: de Dueñas EM; Medical Oncology Department, Provincial Hospital of Castellón, Av. Doctor Clará, 19, 12002, Castellón de la Plana, Spain. eduardo.martinez@hospitalprovincial.es., Gavila-Gregori J; Medical Oncology Department, Valencian Institute of Oncology, Valencia, Spain., Olmos-Antón S; Medical Oncology Department, Provincial Hospital of Castellón, Av. Doctor Clará, 19, 12002, Castellón de la Plana, Spain., Santaballa-Bertrán A; La Fe University Hospital, Valencia, Spain., Lluch-Hernández A; Clinic University Hospital of Valencia, Valencia, Spain., Espinal-Domínguez EJ; Oncology Unit, Pfizer Inc., Madrid, Spain., Rivero-Silva M; Oncology Unit, Pfizer Inc., Madrid, Spain., Llombart-Cussac A; Medical Oncology Department, Arnau de Vilanova University Hospital, Valencia, Spain.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2018 Sep; Vol. 20 (9), pp. 1136-1144. Date of Electronic Publication: 2018 Mar 21.

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

Autor: González-Martín A; Medical Oncology Department, MD Anderson Cancer Center, Madrid, C/ Arturo Soria, 270, 28033 - Madrid. Spain. agonzalezm@seom.org., Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M

Publikováno v: Current cancer drug targets [Curr Cancer Drug Targets] 2016; Vol. 16 (5), pp. 415-28.

Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.

Autor: Zafra-Ceres M; Clinical Biochemistry Services, San Cecilio University Hospital. Avd/ Doctor Olóriz s/n 18012, Granada, Spain., de Haro T, Farez-Vidal E, Blancas I, Bandres F, de Dueñas EM, Ochoa-Aranda E, Gomez-Capilla JA, Gomez-Llorente C

Publikováno v: International journal of medical sciences [Int J Med Sci] 2013 May 27; Vol. 10 (7), pp. 932-7. Date of Electronic Publication: 2013 May 27 (Print Publication: 2013).